FGFR1 and lung adenocarcinoma: FGFR1 true gene amplification occurred in 17.4% of SCC but was also observed in 3/26 (11.5%) tumors with neuroendocrine differentiation and 2/28 (7.1%) never-smokers with lung adenocarcinoma, including a female with a concurrent EGFR L858R mutation.